Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adapted TPF Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
2024-512456-38-00Phase 2Completed
- Sponsor
- GORTEC
- Start
- Apr 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, fluorouracil and cisplatin in Oral Mucosal Carcinoma, oropharyngeal squamous cell carcinoma (OPSCC), squamous cell carcinoma of the hypopharynx and 2 more (2 arms), sponsored by GORTEC. Primary endpoint: Rate of patient success at 8 weeks. Started Apr 2024; status: completed.
02
Drugs
docetaxelfluorouracilcisplatin
03
Conditions
Oral Mucosal Carcinomaoropharyngeal squamous cell carcinoma (OPSCC)squamous cell carcinoma of the hypopharynxlaryngeal squamous cell carcinoma (LSCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-512456-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512456-38-00.